Pharmacokinetics of Venom Toxins and Their Modification by Antivenom Therapy

References

• Al‐Asmari A. K., al‐Abdulla I. H., Crouch R. G., Smith D. C., Sjöström L. Assessment of an ovine antivenom raised against venom from the desert black cobra (Walterinnesia aegyptia). Toxicon 1997; 35: 141–145
   PubMed Web of Science ®Google Scholar
• Audebert F., Sorkine M., Bon C. Envenoming by viper bites in France: clinical gradation and biological quantification by ELISA. Toxicon 1992; 30: 599–609
   PubMed Web of Science ®Google Scholar
• Audebert F., Grosselet O., Sabouraud A., Bon C. Quantitation of venom antigens from European vipers in human serum or urine by ELISA. J. Anal. Toxicol. 1993; 17: 236–240
   PubMed Web of Science ®Google Scholar
• Audebert F., Sorkine M., Robbe‐Vincent A., Bon C. Viper bites in France: clinical and biological evaluation; kinetics of envenomations. Human Exp. Toxicol. 1994a; 13: 683–688
   PubMed Web of Science ®Google Scholar
• Audebert F., Urtizberea M., Sabouraud A., Scherrmann J. M., Bon C. Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits. J. Pharmacol. Exp. Ther. 1994b; 268: 1512–1517
   PubMed Web of Science ®Google Scholar
• Baud F. J., Sabouraud A., Vicaut E., Taboulet P., Lang J., Bismuth C., Rouzioux J. M., Scherrmann J. M. Treatment of severe colchicine overdose with colchicine‐specific Fab fragments. N. Engl. J. Med. 1995; 332: 642–645
   PubMed Web of Science ®Google Scholar
• Bon C. Les venins des serpents et pharmacopées. Les Serpents, C. Bauchot. Bordas, Paris 1994; 194–209
   Google Scholar
• Calmette A. Contribution à l'étude du venin des serpents. Immunisation des animaux et traitement de l'envenimation. Ann. Inst. Pasteur 1894; 8: 275–291
   Google Scholar
• Chippaux J. P., Goyffon M. La sérothérapie antivenimeuse: ses applications, ses limites, son avenir. Bull. Soc. Pathol. Exot. 1991; 84: 286–297
   PubMedGoogle Scholar
• Harry P., de Haro L., Asfar P., David J. M. Evaluation de l'immunothérapie anti‐vipérine par fragments F(ab′)2 purifiés (Viperfav™) par voie veineuse. Presse Méd. 1999; 35: 1929–1934
   Google Scholar
• Karlson‐Stiber C., Persson H., Heath A., Smith D., al‐Abdulla I. H., Sjöström L. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. J. Int. Med. 1997; 241: 53–58
   PubMed Web of Science ®Google Scholar
• Malasit P., Warrell D. A., Chanthavanich P., Viravan C., Mongkolsapaya J., Singhthong B., Supich C. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br. Med. J. 1986; 292: 17–20
   PubMed Web of Science ®Google Scholar
• Meyer W. P., Habib A. G., Onayade A. A., Yakubu A., Smith D. C., Nasidi A., Daudu I. J., Warrell D. A., Theakston R. D. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Am. J. Trop. Med. Hyg. 1997; 56: 291–300
   PubMed Web of Science ®Google Scholar
• Pépin S., Lutsch C., Grandgeorge M., Scherrmann J. M. Snake F(ab′)2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. Pharmaceut. Res. 1995; 12: 1470–1473
   PubMed Web of Science ®Google Scholar
• Pépin‐Covatta S., Lutsch C., Grandgeorge M., Scherrmann J. M. Immuno‐reactivity of a new generation of horse F(ab′)2 preparations against European viper venoms and the tetanus toxin. Toxicon 1997; 35: 411–422
   PubMed Web of Science ®Google Scholar
• Pépin‐Covatta S., Lutsch C., Lang J., Scherrmann J. M. Preclinical assessment of immunoreactivity of a new purified equine F(ab′)2 against European viper venom. J. Pharm. Sci. 1998; 87: 221–225
   PubMed Web of Science ®Google Scholar
• Rivière G., Choumet V., Audebert F., Sabouraud A., Debray M., Scherrmann J. M., Bon C. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J. Pharmacol. Exp. Ther. 1997; 281: 1–8
   PubMed Web of Science ®Google Scholar
• Rivière G., Choumet V., Saliou B., Debray M., Bon C. Absorption and elimination of viper venom after antivenom administration. J. Pharmacol. Exp. Ther. 1998; 285: 490–495
   PubMed Web of Science ®Google Scholar
• Russell F. E. Snake venom immunology: historical and practical considerations. J. Toxicol., Toxin Rev. 1988; 7: 1–82
   Web of Science ®Google Scholar
• Sjöström L., al‐Abdulla I. H., Rawat S., Smith D. C., Landon J. A comparison of ovine and equine antivenoms. Toxicon 1994; 32: 427–433
   PubMed Web of Science ®Google Scholar
• Smith T. W., Lloyd B. L., Spicer N., Haber E. Immunogenicity and kinetics of distribution and elimination of sheep digoxin‐specific IgG and Fab fragments in the rabbit and baboon. Clin. Exp. Immunol. 1979; 36: 384–396
   PubMed Web of Science ®Google Scholar
• Smith T. W., Butler V. P., Jr., Haber E., Fozzard H., Marcus F. I., Bremner W. F., Schulman I. C., Phillips A. Treatment of life‐threatening digitalis intoxication with digoxin‐specific Fab antibody fragments: experience in 26 cases. N. Engl. J. Med. 1982; 307: 1357–1362
   PubMed Web of Science ®Google Scholar
• Smith D. C., Reddi K. R., Laing G., Theakston R. G., Landon J. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 1992; 30: 865–871
   PubMed Web of Science ®Google Scholar
• Theakston R. D. An objective approach to antivenom therapy and assessment of first‐aid measures in snake bite. Ann. Trop. Med. Parasitol. 1997; 91: 857–865
   PubMed Web of Science ®Google Scholar
• Thomas L., Tyburn B., Bucher B., Pecout F., Ketterlé J., Rieux D., Smadja D., Garnier D., Plumelle Y. Prevention of thromboses in human patients with Bothrops lanceolatus envenoming in Martinique: failure of anticoagulants and efficacy of a monospecific antivenom. Research Group on Snake Bites in Martinique. Am. J. Trop. Med. Hyg. 1995; 52: 419–426
   PubMed Web of Science ®Google Scholar
• Thomas L., Tyburn B., Lang J., Ketterlé J. Early infusion of a purified monospecific F(ab′)2 antivenom serum for Bothrops lanceolatus bites in Martinique. Lancet 1996; 347: 406
   PubMed Web of Science ®Google Scholar
• Valentine J. L., Mayersohn M., Wessinger W. D., Arnold L. W., Owens S. M. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine‐induced behavioral effects and ataxia in rats. J. Pharmacol. Exp. Ther. 1996; 278: 709–716
   PubMed Web of Science ®Google Scholar
• Warrell D. A. Clinical features of envenoming of snake bites. Envenoming and Their Treatments, C. Bon, M. Goyffon. Fond. Marcel Mérieux, France 1996; 63–76
   Google Scholar
• World Health Organization, Genova. Progress in the Characterization of Venoms and Standardization of Antivenoms. 1981; Vol. 58
   Google Scholar